Related Experiment Video
Updated: May 27, 2026
08:15
Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
The PSD-95/nNOS complex: new drugs for depression?
Marika V Doucet1, Andrew Harkin, Kumlesh K Dev
1Molecular Neuropharmacology, Department of Physiology, Trinity College, Dublin 2, Ireland.
Pharmacology & Therapeutics
|December 3, 2011
Summary
Current depression treatments targeting monoamines are slow. This review explores the N-methyl-D-aspartate (NMDA) receptor and its associated protein complex as a novel therapeutic target for faster antidepressant effects.
Area of Science:
- Neuroscience
- Pharmacology
- Molecular Biology
Background:
- Current antidepressant drugs primarily target monoaminergic systems, leading to delayed symptom improvement.
- This delay suggests that downstream neuronal adaptations, not immediate monoamine level increases, drive therapeutic effects.
- The N-methyl-D-aspartate (NMDA) receptor is implicated in various central nervous system (CNS) disorders, including depression.
Purpose of the Study:
- To review the molecular mechanisms of NMDA receptor signaling.
- To highlight the role of the NMDA receptor/PSD-95/neuronal nitric oxide synthase (nNOS) complex in CNS disorders.
- To discuss novel drug developments targeting this complex for depression treatment.
Main Methods:
- Review of existing literature on NMDA receptor signaling pathways.
- Analysis of the NMDAR/PSD-95/nNOS complex's involvement in CNS disorders.
- Examination of emerging therapeutic strategies targeting protein-protein interactions.
Main Results:
- NMDA receptor signaling involves complex molecular cascades.
- The NMDAR/PSD-95/nNOS complex plays a significant role in CNS pathophysiology.
- Targeting this complex presents a promising avenue for novel antidepressant drug development.
Conclusions:
- The NMDA receptor, particularly the NMDAR/PSD-95/nNOS complex, represents a viable target for depression therapy.
- Exploiting PDZ-based protein-protein interactions offers innovative therapeutic strategies.
- Further research into NMDA receptor modulation could lead to faster-acting antidepressants.
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:25Antidepressant Drugs: Overview
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:21G-protein Coupled Receptors
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications